NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis $23.37 -0.21 (-0.89%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$23.38 +0.01 (+0.04%) As of 03/14/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About NewAmsterdam Pharma Stock (NASDAQ:NAMS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$22.76▼$24.0050-Day Range$17.53▼$26.0452-Week Range$15.19▼$27.29Volume1.38 million shsAverage Volume487,946 shsMarket Capitalization$2.57 billionP/E RatioN/ADividend YieldN/APrice Target$43.33Consensus RatingBuy Company OverviewNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Read More… Remove Ads NewAmsterdam Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreNAMS MarketRank™: NewAmsterdam Pharma scored higher than 54% of companies evaluated by MarketBeat, and ranked 485th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNewAmsterdam Pharma has only been the subject of 4 research reports in the past 90 days.Read more about NewAmsterdam Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NewAmsterdam Pharma is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NewAmsterdam Pharma is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 6.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NewAmsterdam Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.37% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NewAmsterdam Pharma has recently increased by 4.47%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.37% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NewAmsterdam Pharma has recently increased by 4.47%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment1.35 News SentimentNewAmsterdam Pharma has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NewAmsterdam Pharma this week, compared to 4 articles on an average week. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have sold 10,865.45% more of their company's stock than they have bought. Specifically, they have bought $84,185.00 in company stock and sold $9,231,268.00 in company stock.Percentage Held by Insiders19.50% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NewAmsterdam Pharma's insider trading history. Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Stock News HeadlinesInsider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) Director Buys 4,005 Shares of StockMarch 7, 2025 | insidertrades.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from Piper SandlerMarch 12 at 8:21 AM | markets.businessinsider.com“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…March 15, 2025 | True Market Insiders (Ad)Director’s Bold Move: Major Stock Purchase in NewAmsterdam Pharma!March 6, 2025 | tipranks.comNewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimMarch 3, 2025 | markets.businessinsider.comNewAmsterdam Pharma files for $500M mixed securities shelfMarch 1, 2025 | seekingalpha.comNewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibMarch 1, 2025 | seekingalpha.comNewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of ObicetrapibMarch 1, 2025 | seekingalpha.comSee More Headlines NAMS Stock Analysis - Frequently Asked Questions How have NAMS shares performed this year? NewAmsterdam Pharma's stock was trading at $25.70 at the beginning of 2025. Since then, NAMS stock has decreased by 9.1% and is now trading at $23.37. View the best growth stocks for 2025 here. How were NewAmsterdam Pharma's earnings last quarter? NewAmsterdam Pharma (NASDAQ:NAMS) released its quarterly earnings data on Wednesday, February, 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.47. The firm earned $12.77 million during the quarter, compared to analyst estimates of $3.30 million. Who are NewAmsterdam Pharma's major shareholders? Top institutional investors of NewAmsterdam Pharma include Frazier Life Sciences Management L.P. (17.23%), Bain Capital Life Sciences Investors LLC (11.60%), Fcpm Iii Services B.V. (11.47%) and RA Capital Management L.P. (9.57%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Louis G Lange, Louise Frederika Kooij, Juliette Berangere Audet and Johannes Jacob Piete Kastelein. View institutional ownership trends. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NewAmsterdam Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), PIMCO Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX). Company Calendar Last Earnings2/26/2025Today3/14/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAMS CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$43.33 High Stock Price Target$52.00 Low Stock Price Target$37.00 Potential Upside/Downside+85.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio10.61 Quick Ratio10.61 Sales & Book Value Annual Sales$45.56 million Price / Sales56.33 Cash FlowN/A Price / Cash FlowN/A Book Value$3.50 per share Price / Book6.68Miscellaneous Outstanding Shares109,818,000Free Float74,371,000Market Cap$2.57 billion OptionableOptionable Beta-0.04 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:NAMS) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.